News
January 4, 2007
BioAxone Therapeutic Licenses Phase II Spinal Cord
Injury Drug Cethrin® to Boston Life Sciences December 11, 2006
December 2006: Gazette
Article - Biotech firms face difficult challenges November 27, 2006
BioAxone Therapeutic Study Demonstrates Positive Interim
Results for Spinal Cord Injury November 27, 2006
Major breakthrough at BioAxone Therapeutic (La Presse
Article) August 28, 2006
BioAxone Therapeutic announces patients completed the 6
week follow-up in the Phase I/IIa Trial of Cethrin(R)
for the treatment of acute spinal cord injury July 10, 2006
BioAxone Therapeutic completes patient enrollment for
Phase I/IIa trial of Cethrin(R) in treatment of acute
spinal cord injury June 11, 2006
BioAxone Thérapeutique Inc. implicates itself in the
community with the Rick Hansen Wheels in Motion event . December 19, 2005 BioAxone Therapeutic Inc. announces closing of $5.1 million. December 12, 2005 Cethrin(R) receives Orphan Drug Status. November 28, 2005 To Walk Again: FORBES Magazine looks at
BioAxone. November 28, 2005 BioAxone Appoints Patrick Tremblay Vice President Research & Development
November 21, 2005 For the third time since 2002 and 2003, The Ontario Life Science Council (OLSC) selects BioAxone Therapeutic Inc. as one of Canada’s Top 10 Life Science Companies. September 26, 2005 BioAxone to pursue enrolment of patients with cervical spinal cord injury in phase
I/IIa clinical trial with lead compound Cethrin(R) (BA-210) September 22, 2005 Wall Street Reporter looks at BioAxone Therapeutic for
2005 June 6, 2005Data Safety Monitoring Board recommends continuation of BioAxone's phase I/IIa clinical trial May 19, 2005 BioAxone Therapeutic Inc. announces a second-round investment of $12.15 million March 14, 2005 BioAxone Appoints Frank Bobe President and Chief Executive Officer February 07, 2005 BioAxone announces first patient treatment in acute spinal cord injury trial February 02, 2005 Un traitement expérimental à l'essai pour réparer la moelle épinière January 11, 2005 BioAxone receives FDA approval for acute spinal cord injury trial December 16, 2004 Bioaxone enters clinical studies June 17, 2004 Wall Street Reporter looks at BioAxone Therapeutic for 2004 June 7 , 2004 BioAxone to conduct First Clinical Trial with Cethrin(R) in Spinal Cord Injury June 6 , 2004 BioAxone's Cethrin(R) receives US Patent Notice of Allowance March 15 , 2004 BioAxone Therapeutic Inc. - Appointment January 19 , 2004 BioAxone moves ahead with electronic document management October 6, 2003 BioAxone Therapeutic inc. part of Canada's Top 10 life sciences investment prospects announced for BioNorth 2003 September 4, 2003 Wall Street Reporter presents BioAxone Therapeutic July 31, 2003 BioAxone Therapeutic Making Progress In Spinal Cord Injuries, Cancer, BioWorld Today Article May 6, 2003 BioAxone Therapeutic appoints Dr. Nigel Brown Chairman of the Board
March 17, 2003 BioAxone Therapeutic Inc. signs out-license deal worth $30 Million
September 30, 2002 BioAxone Therapeutic, is nominated one of the top 10 Biotech Companies in Canada July 02, 2002 October 12, 2001 Bioaxone participates in a biopharmaceutical partenership symposium May 15, 2001 MedTech Partners announces investment in BioAxone Therapeutic Inc November 15, 2000 Université de Montréal researcher receives Christopher Reeve Medal The Christopher Reeve Paralyis Foundation holds black-tie fund-raising evening and awards Dr. Albert Aguayo and Dr. Lisa McKerracher The Christopher Reeve Research Medal. Christopher Reeves Paralysis Foundation
© BioAxone Thérapeutique
Inc. 2005